Allergan asks FDA to approve Oculeve neurostim device

Allergan (NYSE:AGN) said today that it filed a de novo approval application with the FDA for its Oculeve nasal neurostimulation device for dry eye it bought last year. Oculeve is a hand-held device designed to be inserted into the nostril to stimulate the nerves serving the lacrimal gland. Allergan paid $125 million plus unspecified milestones for Oculeve last year. The de novo protocol is for low- to moderate-risk devices that don’t have a “substantially equivalent predecessor” device already on the market. “The Oculeve intranasal tear neurostimulator is an exciting potential option for patients suffering from dry eye disease, and we are pleased to have filed the de novo application with FDA that will allow patients to gain access to this novel medical device,” chief R&D officer David Nicholson said in prepared remarks. In May the company said a pair of pivotal trials passed their safety and efficacy endpoints, clearing the way for a pre-market approval submission. The 48-patient OCUN-009 trial evaluated intra- and extra-nasal use of the Oculeve device compared with sham intra- and extra-nasal treatments at 6 months, using a safety endpoint of device-related adverse events and an efficacy endpoint of tear production during treatment with tear production during the sham applications. Allergan said the study met the efficacy endpoint. The 2nd study, OCUN-010, tracked 97 subjects who used the Oculev...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Optical/Ophthalmic Regulatory/Compliance Allergan Inc. Oculeve Source Type: news

Related Links:

Conclusions: Keeping a dog at home before and during pregnancy decreased the risk of food allergy in 1-year-old children. This effect was eliminated in case of having a cat, hamster, guinea pig, or rabbit. PMID: 32489363 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Authors: Diaz JH Abstract Red meat allergies have followed tick bites on every continent except Antarctica. The sensitizing antigen is galactose-α-1,3-galactose (α-gal), an oligosaccharide constituent of nonprimate blood and meat, acquired by ticks during animal bloodfeeding. Because red meat allergy after tick bites is a worldwide phenomenon, the objectives of this review were to describe the global epidemiology of red meat allergy after tick bites and its immunological mechanisms; to identify the human risk factors for red meat allergy after tick bites; to identify the most common tick vectors of red ...
Source: Southern Medical Journal - Category: General Medicine Tags: South Med J Source Type: research
Additionally, side effects were more common among participants in the HCQ group than the placebo group. One expert says the results raise the question of whether some ongoing trials should stop.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
The vast majority of people with a penicillin allergy label are, in fact, not allergic, leading to significant healthcare implications. Experts say it is now time for a national “de-labelling” drive to help conserve vital antibiotics.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
An analysis of hospital admissions data by  The Pharmaceutical Journal shows that between 2012/2013 and 2018/2019, the number of hospital admissions in England where the patient had a diagnostic ‘label’ of penicillin allergy almost doubled, from 575,000 to 1.1 million.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Oral corticosteroids (OCS) are used to manage asthma exacerbations and severe, uncontrolled asthma, but OCS use is associated with adverse effects. We aimed to describe the patterns of OCS use in the real-world management of patients with asthma in western Europe. We used electronic medical records from databases in France, Germany, Italy and the United Kingdom from July 2011 through February 2018. Patients aged ≥12 years with an asthma diagnosis, at least one non-OCS asthma medication within ±6 months of diagnosis, and available data ≥6 months prior to and ≥90 days after cohort entry we...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Asthma and allergy Original Articles: Asthma Source Type: research
The United States should have 100 million doses of one candidate coronavirus vaccine by the end of the year, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and a member of the White House Coronavirus Task Force, said Tuesday.
Source: - Health - Category: Consumer Health News Source Type: news
Publication date: Available online 3 June 2020Source: Journal of Hospital InfectionAuthor(s): Neil Powell, Kate Honeyford, Jonathan Sandoe
Source: Journal of Hospital Infection - Category: Infectious Diseases Source Type: research
WEDNESDAY, June 3, 2020 -- According to Anthony Fauci, M.D., director of the U.S. National Institute of Allergy and Infectious Diseases, 100 million doses of a coronavirus vaccine will be available by year's end. " Then, by the beginning of 2021, we...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
Publication date: Available online 3 June 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Clémence David, Marie Jachiet, Marc Pineton de Chambrun, Anne Sophie Gamez, Anas Mehdaoui, Thierry Zenone, Delphine Gobert, Achille Aouba, Anne Peterschmitt, Sylvain Palat, François Lifermann, Daniel Blockmans, Séverine Feuillet-Soummer, Luc Mouthon, Benjamin Terrier, French Vasculitis Study Group
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
More News: Allergy | Medical Devices | Neurology | Opthalmology | Restasis | Study